Expert opinion on emerging drugs: chronic low back pain
Authors:
- Sunberri MurphySMSunberri Murphy
- David ChangDCDavid Chang
- Steven P CohenSCSteven P Cohen
- 18 December 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 20 (1) , 103-127
Abstract
It is difficult to overestimate the personal and socioeconomic impact of chronic low back pain (CLBP). It is the leading cause of years lost to disability and poses the highest economic toll among chronic illnesses. Despite the strong need for extensive research efforts, few drugs have consistently demonstrated effectiveness for this condition. In this review, the epidemiology, rationale for mechanism-based treatment, competitive environment and market trends, and the preclinical and clinical evidence supporting over 15 different classes of analgesic medications studied for CLBP or related pain conditions are discussed. Treatments are divided by drug category, type of CLBP they are likely to treat (e.g., neuropathic or mechanical), and whether they are new formulations of existing treatments, new indications for existing treatments or represent novel mechanisms of action. Databases searched included MEDLINE, Embase, Pharmaprojects and various clinical trial registries. Many barriers exist for the development of medications for CLBP including difficulties in identifying pathophysiological mechanisms, biologic resiliency secondary to multiple concurrent pain pathways and off-target and sometimes serious side effects. Nevertheless, the volume and diversity of novel molecular entities has continued to surge and includes possible disease-modifying therapies such as gene and stem cell therapy.Keywords
This publication has 173 references indexed in Scilit:
- Aging Baby Boomers and the Rising Cost of Chronic Back Pain: Secular Trend Analysis of Longitudinal Medical Expenditures Panel Survey Data for Years 2000 to 2007Journal of Manipulative and Physiological Therapeutics, 2013
- Forebrain GABAergic Neuron Precursors Integrate into Adult Spinal Cord and Reduce Injury-Induced Neuropathic PainNeuron, 2012
- Toll-like receptors in chronic painExperimental Neurology, 2012
- Emerging role of Toll-like receptors in the control of pain and itchNeuroscience Bulletin, 2012
- Gene therapy for pain: Results of a phase I clinical trialAnnals of Neurology, 2011
- Surgery versus conservative management of sciatica due to a lumbar herniated disc: a systematic reviewEuropean Spine Journal, 2010
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Pregabalin, celecoxib, and their combination for treatment of chronic low-back painJournal of Orthopaedics and Traumatology, 2009
- Effect sizes of non-surgical treatments of non-specific low-back painEuropean Spine Journal, 2007
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000